Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine (131I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and periodically reviewed in order to identify potential biological markers exploitable for target therapy. This review briefly focuses on main molecular events that characterize ATC and provides an update about preclinical studies. In addition, the overexpression of transferrin receptor 1 (TfR1/CD71) by neoplastic cells of ATC is emphasized in that it could represent a potential therapeutic target. In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed.

[1]  M. Shah,et al.  Anaplastic thyroid cancer , 2015, Current opinion in endocrinology, diabetes, and obesity.

[2]  C. Nucera,et al.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF , 2014, Oncogene.

[3]  T. Jacks,et al.  p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer , 2014, Proceedings of the National Academy of Sciences.

[4]  B. Burkey,et al.  Anaplastic thyroid cancer in young patients: a contemporary review. , 2013, American journal of otolaryngology.

[5]  D. Glavač,et al.  MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer , 2013, Radiology and oncology.

[6]  V. D. Di Crescenzo,et al.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.

[7]  Richard J. Lee,et al.  Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. , 2013, Thyroid : official journal of the American Thyroid Association.

[8]  M. Merlano,et al.  The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer , 2013, OncoTargets and therapy.

[9]  Fazlul H. Sarkar,et al.  Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy , 2013, International journal of molecular sciences.

[10]  T. Fahey,et al.  Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. , 2013, The Journal of surgical research.

[11]  Jung-Ah Hwang,et al.  Recent Progress of Genome Study for Anaplastic Thyroid Cancer , 2013, Genomics & informatics.

[12]  A. Pontecorvi,et al.  Diagnostic and Prognostic Role of HBME-1, Galectin-3, and &bgr;-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas , 2013, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  W. Sewell,et al.  An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma , 2013, Journal of visualized experiments : JoVE.

[14]  M. Pellegrini,et al.  Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  S. Roman,et al.  New targeted therapies and other advances in the management of anaplastic thyroid cancer , 2013, Current opinion in oncology.

[16]  F. Frasca,et al.  Update on thyroid cancer treatment. , 2012, Future oncology.

[17]  Christopher R Chitambar,et al.  Gallium-containing anticancer compounds. , 2012, Future medicinal chemistry.

[18]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[19]  C. Nucera,et al.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. , 2012, Endocrinology.

[20]  C. Montagna,et al.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors , 2011, Oncotarget.

[21]  J. M. Gómez Sáez.  Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer , 2011, Current genomics.

[22]  Dagmara Rusinek,et al.  Gene expression profile of human thyroid cancer in relation to its mutational status. , 2011, Journal of molecular endocrinology.

[23]  M. Pellegrini,et al.  Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells , 2011, Leukemia & lymphoma.

[24]  G. Magro,et al.  Pitfalling in nanomedical targeting of melanoma: a ‘clinical’ case of misdelivered RNAi , 2011, Pigment cell & melanoma research.

[25]  T. Daniels,et al.  An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies , 2011, Journal of immunotherapy.

[26]  R. Weber,et al.  Anaplastic thyroid carcinoma: palliation or treatment? , 2011, Current opinion in otolaryngology & head and neck surgery.

[27]  R. Parenti,et al.  Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. , 2011, Thyroid : official journal of the American Thyroid Association.

[28]  Emma Lundsmith,et al.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice , 2011, Proceedings of the National Academy of Sciences.

[29]  A. Di Cristofano,et al.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females , 2010, Oncogene.

[30]  G. Magro,et al.  Warthin Tumor-Like Papillary Thyroid Carcinoma with a Minor Dedifferentiated Component: Report of a Case with Clinicopathologic Considerations , 2010, Case reports in medicine.

[31]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[32]  E. Hey‐Hawkins,et al.  Novel gallium(III) complexes containing phthaloyl derivatives of neutral aminoacids with apoptotic activity in cancer cells , 2009 .

[33]  A. Di Cristofano,et al.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. , 2009, Cancer research.

[34]  S. Devesa,et al.  Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005 , 2009, Cancer Epidemiology Biomarkers & Prevention.

[35]  J. Copland,et al.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.

[36]  V. Trovisco,et al.  Intragenic mutations in thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[37]  H. Namba,et al.  Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells , 2008, Cancer science.

[38]  T. Yao,et al.  HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization* , 2008, Journal of Biological Chemistry.

[39]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[40]  Yuri E Nikiforov,et al.  Thyroid carcinoma: molecular pathways and therapeutic targets , 2008, Modern Pathology.

[41]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[42]  G. Wakabayashi,et al.  Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines , 2008, Cancer science.

[43]  M. Nikiforova,et al.  Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis , 2008, Expert review of molecular diagnostics.

[44]  Francesco Trimarchi,et al.  What is New on Thyroid Cancer Biomarkers , 2008, Biomarker insights.

[45]  V. Detours,et al.  Gene expression and the biological phenotype of papillary thyroid carcinomas , 2007, Oncogene.

[46]  C. Croce,et al.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.

[47]  M. Bittner,et al.  A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. , 2007, Cancer research.

[48]  Meiying Yang,et al.  Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate , 2007, Journal of Pharmacology and Experimental Therapeutics.

[49]  S. Filetti,et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.

[50]  Jyotika K. Fernandes,et al.  Anaplastic thyroid carcinoma: An overview , 2007, Current oncology reports.

[51]  J. Brierley,et al.  An evidence-based review of poorly differentiated thyroid cancer , 2007, World Journal of Surgery.

[52]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[53]  Ashish Rajput,et al.  Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment , 2007, Annals of Surgical Oncology.

[54]  S. Matsuyama,et al.  Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition , 2006, Molecular Cancer Therapeutics.

[55]  T. Daniels,et al.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.

[56]  Gustavo Helguera,et al.  The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.

[57]  J. El Hage Chahine,et al.  Gallium uptake by transferrin and interaction with receptor 1 , 2006, JBIC Journal of Biological Inorganic Chemistry.

[58]  W. Zhihua,et al.  The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor , 2006, Cancer Immunology, Immunotherapy.

[59]  C. Croce,et al.  MicroRNA deregulation in human thyroid papillary carcinomas. , 2006, Endocrine-related cancer.

[60]  S. Wiseman,et al.  Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. , 2006, American journal of surgery.

[61]  A. Shaha,et al.  Poorly differentiated and anaplastic thyroid cancer. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[62]  A. Harris,et al.  Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. , 2006, Cancer Research.

[63]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[65]  P. Gattuso,et al.  Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations , 2005, Cancer.

[66]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[67]  E. Kebebew,et al.  Anaplastic thyroid carcinoma , 2005, Cancer.

[68]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[69]  N. Socci,et al.  Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker , 2004, Cancer Research.

[70]  K. Pantopoulos.  Iron Metabolism and the IRE/IRP Regulatory System: An Update , 2004, Annals of the New York Academy of Sciences.

[71]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[72]  S. Finkelstein,et al.  Molecular Evidence of Anaplastic Transformation in Coexisting Well-Differentiated and Anaplastic Carcinomas of the Thyroid , 2003, The American journal of surgical pathology.

[73]  R. Weissleder,et al.  The transferrin receptor: a potential molecular imaging marker for human cancer. , 2003, Neoplasia.

[74]  R. Camp,et al.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  A. Belfiore,et al.  Differential expression of mucins 1–6 in papillary thyroid carcinoma: evidence for transformation‐dependent post‐translational modifications of MUC1 in situ , 2003, The Journal of pathology.

[76]  M. Bisceglia,et al.  Proteomic and postproteomic characterization of keratan sulfate-glycanated isoforms of thyroglobulin and transferrin uniquely elaborated by papillary thyroid carcinomas. , 2003, The American journal of pathology.

[77]  M. Ringel,et al.  Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[78]  J. Shah,et al.  Genome-wide appraisal of thyroid cancer progression. , 2002, The American journal of pathology.

[79]  M. Willingham,et al.  Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. , 2002, Thyroid : official journal of the American Thyroid Association.

[80]  S. Morrison,et al.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Santoro,et al.  Thyroid cell transformation requires the expression of the HMGA1 proteins , 2002, Oncogene.

[82]  G. Thompson,et al.  Anaplastic thyroid carcinoma: a 50-year experience at a single institution. , 2001, Surgery.

[83]  J. Quivey,et al.  Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival , 2001, Cancer.

[84]  I. Sugitani,et al.  Prognostic Factors and Therapeutic Strategy for Anaplastic Carcinoma of the Thyroid , 2001, World Journal of Surgery.

[85]  D. Rimm,et al.  β-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis , 2001 .

[86]  M. Willingham,et al.  Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Leppäniemi,et al.  Anaplastic Thyroid Carcinoma Survival , 1999, World Journal of Surgery.

[88]  D. Rimm,et al.  Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. , 1999, Cancer research.

[89]  O. Ozaki,et al.  Anaplastic transformation of papillary thyroid carcinoma in recurrent disease in regional lymph nodes: A histologic and immunohistochemical study , 1999, Journal of surgical oncology.

[90]  L R Bernstein,et al.  Mechanisms of therapeutic activity for gallium. , 1998, Pharmacological reviews.

[91]  H. Blomgren,et al.  Anaplastic Giant Cell Carcinoma of the Thyroid Gland: Treatment and Survival Over a 25-Year Period , 1998, World Journal of Surgery.

[92]  A. Houghton,et al.  Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  G. Chiappetta,et al.  The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. , 1995, Oncogene.

[94]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[95]  K. Shimokata,et al.  Relationship between gallium 67 citrate scanning and transferrin receptor expression in lung diseases. , 1992, Chest.

[96]  A. Lawrence,et al.  Anaplastic thyroid carcinoma: risk factors and outcome. , 1991, Surgery.

[97]  N. Ordóñez,et al.  Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases , 1990, Cancer.

[98]  M. Noguchi,et al.  Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. , 1990, Chest.

[99]  C. Chitambar,et al.  Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. , 1987, Cancer research.

[100]  P. Seligman,et al.  Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. , 1986, The Journal of clinical investigation.

[101]  T. Mimura,et al.  The relationships between the Ga-67 uptake and nuclear DNA Feulgen content in thyroid tumors: concise communication. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[102]  O. Senga,et al.  Comparison of Tl-201 chloride and Ga-67 citrate scintigraphy in the diagnosis of thyroid tumor: concise communication. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  G. Tallini,et al.  Molecular diagnosis of carcinomas of the thyroid gland. , 2014, Frontiers in bioscience.

[104]  M. Penichet,et al.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti‐transferrin receptor antibodies and an immunoglobulin promoter , 2014, The journal of gene medicine.

[105]  S. Goswami,et al.  Among the three striatin family members, SG2NA was first to arise during evolution. , 2014, Frontiers in bioscience.

[106]  C. Binns.  Tutorial Section on Nanomagnetism , 2014 .

[107]  T. Gross,et al.  BRAF V600E Inhibition in Anaplastic Thyroid Cancer , 2013 .

[108]  M. Schott.  The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer , 2010 .

[109]  A. Renand,et al.  Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody , 2008, Leukemia.

[110]  Y. Nikiforov.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas , 2004, Endocrine pathology.

[111]  A. Muzikansky,et al.  The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma , 2002, Annals of Surgical Oncology.

[112]  D. Rimm,et al.  Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. , 2001, The American journal of pathology.

[113]  C. Brocheriou.  [Anaplastic carcinoma of the thyroid]. , 1998, Archives d'anatomie et de cytologie pathologiques.

[114]  J. Sagartz,et al.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.

[115]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[116]  R. Miller,et al.  Anaplastic Thyroid Carcinoma: Association With Differentiated Thyroid Cancer , 1988 .

[117]  N. Samaan,et al.  Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. , 1978, Cancer.

[118]  M. Crescenzi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Effects of Exogenous p53 Transduction in Thyroid Tumor Cells with Different p53 Status* , 2022 .